Johnson & Johnson $JNJ Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 643,935 shares of the company’s stock after selling 19,732 shares during the quarter. Johnson & Johnson comprises approximately 2.1% of Douglas Lane & Associates LLC’s portfolio, making the stock its 9th biggest holding. Douglas Lane & Associates LLC’s holdings in Johnson & Johnson were worth $170,475,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. National Pension Service increased its position in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock valued at $1,327,493,000 after buying an additional 67,484 shares during the period. IFP Advisors Inc lifted its holdings in shares of Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B boosted its stake in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock worth $7,285,000 after buying an additional 2,563 shares during the last quarter. Signal Advisors Wealth LLC lifted its stake in shares of Johnson & Johnson by 76.1% in the 1st quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock worth $3,697,000 after purchasing an additional 6,539 shares during the period. Finally, Gradient Investments LLC lifted its position in Johnson & Johnson by 9.9% during the second quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after purchasing an additional 13,737 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on JNJ shares. Citigroup upped their price target on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday. TD Cowen boosted their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Scotiabank restated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Wells Fargo & Company upped their target price on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $276.22.

Johnson & Johnson Trading Up 1.8%

Shares of JNJ stock traded up $4.52 on Friday, hitting $261.00. The stock had a trading volume of 1,827,529 shares, compared to its average volume of 7,939,630. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The company’s 50 day moving average price is $265.73 and its 200-day moving average price is $248.93. The firm has a market capitalization of $628.99 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.59 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter last year, the company posted $2.77 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.3 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong long-term psoriasis data: Johnson & Johnson reported two-year Phase 3 results for ICOTYDE® (icotrokinra), with nearly three-quarters of adults and adolescents achieving clear or almost clear skin and a favorable safety profile. The data support the drug’s commercial prospects and could strengthen JNJ’s pharmaceutical pipeline. ICOTYDE two-year data
• Positive Sentiment: Analyst support: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. Separate commentary highlights JNJ as a potential faster-growth healthcare company, helping support investor confidence despite its premium valuation. Guggenheim Buy rating
• Positive Sentiment: Income-investor appeal: Articles continue to feature JNJ as a Dividend Aristocrat with a long record of dividend growth and comparatively reliable cash generation. That defensive profile may attract investors seeking stability amid healthcare-sector uncertainty. Healthcare Dividend Aristocrats
• Neutral Sentiment: Earnings expectations remain constructive: Analysts are looking for another earnings beat, and previews focus on September-quarter operating metrics. However, these reports are forecasts rather than confirmed results, leaving execution and forward guidance as the next catalysts. JNJ Q3 earnings preview
• Negative Sentiment: Patent-cliff risk persists: Upcoming patent expirations for cancer medicines Imbruvica and Darzalex could pressure pharmaceutical revenue over the next several years. Management’s pipeline investments and dealmaking may mitigate the impact, but investors remain focused on whether new products can replace lost exclusivity. JNJ patent cliff

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last quarter. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.